Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock

$1.41

4.08% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

CA14161Y2006

Symbol

CRDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock price

$1.41

-0.34 19.57% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.06 4.08%

ISIN

CA14161Y2006

Symbol

CRDL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$121.2m

Enterprise Value

$104.3m

Net debt

$-16.9m

Cash

$17.0m

Shares outstanding

82.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

9.08

Financial Health

Equity Ratio

77.61%

Return on Equity

-148.32%

ROCE

-227.66%

ROIC

Debt/Equity

0.01

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-29.2m | $-22.5m

EBIT

$-29.4m

Net Income

$-26.1m | $-31.7m

Free Cash Flow

$-18.5m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-32.61% | 22.85%

EBIT

-32.55%

Net Income

-18.42% | -18.32%

Free Cash Flow

-14.15%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-0.31

FCF per Share

$-0.22

Short interest

2.40%

Employees

18.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Cardiol Therapeutics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	19 19	53% 53% -
- Research and Development Expense	11 11	8% 8% -
EBITDA	-29 -29	33% 33% -
- Depreciation and Amortization	0.23 0.23	28% 28% -
EBIT (Operating Income) EBIT	-29 -29	33% 33% -
Net Profit	-26 -26	18% 18% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock News

Positive

Proactive Investors

●

4 months ago

Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new research published in the Journal of the American College of Cardiology: Basic to Translational Science (JACBTS) supports the potential of its cannabidiol-based drug candidate CRD-38 to treat heart failure. The study, conducted by scientists at Tecnológico de Monterrey in collaboration with researchers from the DeBakey Heart and Vascula...

Company Profile

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Head office	Canada
CEO	David Elsley
Employees	18
Founded	2017
Website	www.cardiolrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now